Vertex Pharmaceuticals Inc
VRTXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Vertex Pharmaceuticals Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 18 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 30, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| WHITTIER TRUST CO | 2026-03-31 | 1,830 | $795K | SEC filing |
| EVOLUTION WEALTH MANAGEMENT INC. | 2026-03-31 | 52 | $23.2K | SEC filing |
| Aigen Investment Management, LP | 2026-03-31 | 4,238 | $1.89M | SEC filing |
| NEUBERGER BERMAN GROUP LLC | 2026-03-31 | 551,522 | $246M | SEC filing |
| Cladis Investment Advisory, LLC | 2026-03-31 | 542 | $242K | SEC filing |
| Generali Investments CEE, investicni spolecnost, a.s. | 2026-03-31 | 10,599 | $4.73M | SEC filing |
| Atle Fund Management AB | 2026-03-31 | 22,984 | $11.2M | SEC filing |
| Mutual Advisors, LLC | 2026-03-31 | 3,509 | $1.57M | SEC filing |
| ZACKS INVESTMENT MANAGEMENT | 2026-03-31 | 55,082 | $24.6M | SEC filing |
| Covestor Ltd | 2026-03-31 | 303 | Not shown | SEC filing |
| Torrey Growth & Income Advisors | 2026-03-31 | 4,710 | $2.09M | SEC filing |
| EVOKE WEALTH, LLC | 2026-03-31 | 1,485 | $663K | SEC filing |
| FSM Wealth Advisors, LLC | 2026-03-31 | 864 | $386K | SEC filing |
| NICOLET BANKSHARES INC | 2026-03-31 | 1,417 | $633K | SEC filing |
| CULLINAN ASSOCIATES INC | 2026-03-31 | 51,762 | $23.1M | SEC filing |
| BANK OF MONTREAL /CAN/ | 2026-03-31 | 390,476 | $174M | SEC filing |
| FAGAN ASSOCIATES, INC. | 2026-03-31 | 26,553 | $11.9M | SEC filing |
| VISTA INVESTMENT MANAGEMENT | 2026-03-31 | 1,649 | $736K | SEC filing |
| Urban Wealth Management, LLC | 2026-03-31 | 991 | $443K | SEC filing |
| APPLETON PARTNERS INC/MA | 2026-03-31 | 1,789 | Not shown | SEC filing |
- Each value is checked against Vertex Pharmaceuticals Inc's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 2 rows: the filed value is about 1,000 times too small for the share count at Vertex Pharmaceuticals Inc's share price.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Vertex Pharmaceuticals Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-27 · Kewalramani Reshma: Larger than 96 of the 101 other insider sales of Common Stock on file. SEC filing
- 2026-02-19 · Sachdev Amit: Larger than 93 of the 101 other insider sales of Common Stock on file. SEC filing
- 2026-02-19 · Sachdev Amit: Larger than 95 of the 101 other insider sales of Common Stock on file. SEC filing
- 2026-02-19 · Sachdev Amit: Larger than 99 of the 101 other insider sales of Common Stock on file. SEC filing
- 2026-01-06 · WAGNER CHARLES F JR: Larger than 92 of the 101 other insider sales of Common Stock on file. SEC filing
- 2025-12-03 · LEIDEN JEFFREY M: Larger than 94 of the 101 other insider sales of Common Stock on file. SEC filing
- 2025-12-03 · LEIDEN JEFFREY M: Larger than 97 of the 101 other insider sales of Common Stock on file. SEC filing
- 2025-12-03 · LEIDEN JEFFREY M: Larger than 91 of the 101 other insider sales of Common Stock on file. SEC filing
- 2025-11-14 · LEIDEN JEFFREY M: Larger than all 101 other insider sales of Common Stock on file. SEC filing
- 2025-11-14 · LEIDEN JEFFREY M: Larger than 100 of the 101 other insider sales of Common Stock on file. SEC filing
- 2025-11-13 · LEIDEN JEFFREY M: Larger than 98 of the 101 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-26 | Bozic Carmen · EVP and CMO | Common Stock | S — Open market or private sale | −596 | 482.50 | SEC filing |
| 2026-06-18 | Bozic Carmen · EVP and CMO | Common Stock | S — Open market or private sale | −1,020 | 462.17 | SEC filing |
| 2026-06-15 | Bozic Carmen · EVP and CMO | Common Stock | S — Open market or private sale | −4,062 | 450.00 | SEC filing |
| 2026-06-05 | Bozic Carmen · EVP and CMO | Common Stock | S — Open market or private sale | −1,745 | 450.00 | SEC filing |
| 2026-06-01 | Liu Joy · EVP and Chief Legal Officer | Common Stock | S — Open market or private sale | −828 | 439.91 | SEC filing |
| 2026-05-29 | Bozic Carmen · EVP and CMO | Common Stock | S — Open market or private sale | −1,974 | 450.00 | SEC filing |
| 2026-05-15 | Bozic Carmen · EVP and CMO | Common Stock | S — Open market or private sale | −1,354 | 453.45 | SEC filing |
| 2026-05-15 | Bunnage Mark E. · EVP, Chief Scientific Officer | Common Stock | S — Open market or private sale | −33 | 453.45 | SEC filing |
Showing 8 of 14 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-01 | Upadhyay Suketu · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +2,866 | SEC filing |
| 2026-05-01 | Schneider Jennifer · Director | Common Stock | A — Grant, award, or other acquisition | +472 | SEC filing |
| 2026-05-01 | MCKENZIE DIANA · Director | Common Stock | A — Grant, award, or other acquisition | +943 | SEC filing |
| 2026-05-01 | Lagarde Michel · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +2,866 | SEC filing |
| 2026-05-01 | Garber Alan M · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +1,433 | SEC filing |
| 2026-05-01 | Schneider Jennifer · Director | Deferred Stock Units | A — Grant, award, or other acquisition | +796 | SEC filing |
| 2026-05-01 | Bhatia Sangeeta N. · Director | Common Stock | A — Grant, award, or other acquisition | +943 | SEC filing |
| 2026-05-01 | Thornberry Nancy · Director | Common Stock | A — Grant, award, or other acquisition | +472 | SEC filing |
Showing 8 of 31 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-01 | Schneider Jennifer · Director | Common Stock | D — Disposition to the issuer | −796 | SEC filing |
| 2026-05-01 | Upadhyay Suketu · Director | Common Stock | D — Disposition to the issuer | −796 | SEC filing |
| 2026-05-01 | MCKENZIE DIANA · Director | Common Stock | D — Disposition to the issuer | −796 | SEC filing |
| 2026-05-01 | Thornberry Nancy · Director | Common Stock | D — Disposition to the issuer | −398 | SEC filing |
| 2025-05-01 | Upadhyay Suketu · Director | Common Stock | D — Disposition to the issuer | −1,001 | SEC filing |
| 2025-05-01 | MCKENZIE DIANA · Director | Common Stock | D — Disposition to the issuer | −1,001 | SEC filing |
Showing 6 of 6 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.